New study tracks how kids with arthritis fare on Long-Term secukinumab
NCT ID NCT07190053
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 100 children aged 6 to 17 with juvenile psoriatic or enthesitis-related arthritis who are taking secukinumab. Researchers will observe how doctors adjust treatment after the disease becomes inactive, and whether patients experience flares. The goal is to learn the best long-term strategies for managing these conditions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- secukinumab
- What this could lead to
- If successful, this study could help doctors understand the best long-term strategies for managing juvenile arthritis with secukinumab, potentially reducing flares and medication burden.
- What could go wrong
- This is an observational study, not a controlled trial, so results may not prove cause and effect. It is also small (100 participants) and only includes children from Germany, limiting generalizability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Sep 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Children and adolescents diagnosed with ERA or JPsA JIA categories who received secukinumab
- Ages
-
6 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * In the BIKER registry, males and females ≥ 6 years old and ≤ 17 years old diagnosed with ERA according to the ILAR-criteria or JPsA according to the ILAR or the Vancouver criteria, who initiated at least one dose of secukinumab after it was approved in Germany and according to the label. * Written informed consent from parent/legal guardian and assent from minor patient (11-17 years of age) for participating in the BIKER registry and for this study enrolment. Exclusion Criteria: * Patients taking other biologic immunomodulating agent(s) or Janus kinase (JAK) inhibitors concomitantly with secukinumab at index date. * Patients participating in any interventional trials at index date.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Enthesitis-related arthritis (ERA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.